revivapharma.comCrawled Nov 20, 2026
The company’s lead drug candidate, brilaroxazine (RP5063), is in clinical development for neuropsychiatric indications with unmet needs.
Reviva Pharmaceuticals hosts a virtual event on May 3rd to discuss unmet medical needs and therapeutic opportunities in schizophrenia and major neuropsychiatric disorders.
A clinical trial in 234 patients with acute schizophrenia or schizoaffective disorder meets safety and efficacy endpoints, including PANSS score reduction and improved social functioning.
Reviva Pharmaceuticals prices an upsized public offering of 8,000,000 shares to fund its operations.
Reviva Pharmaceuticals completes a closed merger with Tenzing Acquisition Corp and lists on NASDAQ Capital Market, with plans for a Phase 3 schizophrenia trial in mid-2021.
Reviva Pharmaceuticals announces plans to present at the Maxim Group conference, highlighting therapies for unmet needs in CNS, cardiovascular, metabolic, and inflammatory diseases.
Reviva Pharmaceuticals announces its subsidiary will present at an upcoming conference, focusing on therapies for central nervous system, cardiovascular, metabolic, and inflammatory diseases.
Reviva Pharmaceuticals Holdings and Reviva Pharmaceuticals will trade on NASDAQ under tickers RVPH and RVPHW following their merger.
Reviva's advisory board consists of highly successful, experienced and qualified professionals associated with Pharmaceutical and medical industries.
Reviva's board of directors consists of highly successful, experienced and qualified individuals.
Developing next-generation therapeutics for central nervous system, respiratory, and metabolic diseases of huge unmet need.
Reviva Pharmaceuticals, Inc. confidential financial concern whistleblower hotline.
Developing therapies that seek to address unmet medical needs in the areas of central nervous system, cardiovascular, metabolic, and inflammatory diseases.